Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT

F. Baron, M. Labopin, J. Tischer, AM. Raiola, J. Vydra, D. Blaise, P. Chiusolo, F. Stölzel, R. Fanin, P. Chevallier, A. Nagler, F. Ciceri, M. Mohty

. 2023 ; 16 (1) : 10. [pub] 20230213

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu dopisy, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23004187

The association between graft-versus-host disease (GVHD) occurrence and acute myeloid leukemia (AML) relapse in patients treated with HLA-haploidentical allogeneic hematopoietic stem cell transplantation (Haplo-HCT) with post-transplant cyclophosphamide (PTCy)-based GVHD prophylaxis has remained debated. Here, we addressed this issue in patients with active AML at transplantation. 2-year cumulative incidences of relapse and leukemia-free survival (LFS) were 49% and 32.3%, respectively. There were no associations between acute nor chronic GVHD of any grade and lower relapse incidence. However, grade I acute GVHD was associated with better LFS (HR = 0.71, 95% CI 0.51-0.99, P = 0.04). In contrast, grade III-IV acute (HR = 3.09, 95% CI 1.87-5.12, P < 0.0001) as well as extensive chronic (HR = 3.3, 95% CI 1.81-6.04, P = 0.0001) GVHD correlated with higher nonrelapse mortality leading to lower LFS (HR = 1.36, 95% CI 0.99-1.86, P = 0.056 and HR = 1.97, 95% CI 1.35-2.89, P = 0.0004, respectively). In conclusion, these data suggest a dissociation of graft-versus-leukemia effects from GVHD in patients with active AML treated with PTCy-based Haplo-HCT.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004187
003      
CZ-PrNML
005      
20240528143559.0
007      
ta
008      
230418s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13045-023-01403-x $2 doi
035    __
$a (PubMed)36782226
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Baron, Frédéric $u Laboratory of Hematology, GIGA-I3, University of Liege and CHU of Liège, Sart-Tilman, 4000, Liège, Belgium. f.baron@ulg.ac.be
245    10
$a GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT / $c F. Baron, M. Labopin, J. Tischer, AM. Raiola, J. Vydra, D. Blaise, P. Chiusolo, F. Stölzel, R. Fanin, P. Chevallier, A. Nagler, F. Ciceri, M. Mohty
520    9_
$a The association between graft-versus-host disease (GVHD) occurrence and acute myeloid leukemia (AML) relapse in patients treated with HLA-haploidentical allogeneic hematopoietic stem cell transplantation (Haplo-HCT) with post-transplant cyclophosphamide (PTCy)-based GVHD prophylaxis has remained debated. Here, we addressed this issue in patients with active AML at transplantation. 2-year cumulative incidences of relapse and leukemia-free survival (LFS) were 49% and 32.3%, respectively. There were no associations between acute nor chronic GVHD of any grade and lower relapse incidence. However, grade I acute GVHD was associated with better LFS (HR = 0.71, 95% CI 0.51-0.99, P = 0.04). In contrast, grade III-IV acute (HR = 3.09, 95% CI 1.87-5.12, P < 0.0001) as well as extensive chronic (HR = 3.3, 95% CI 1.81-6.04, P = 0.0001) GVHD correlated with higher nonrelapse mortality leading to lower LFS (HR = 1.36, 95% CI 0.99-1.86, P = 0.056 and HR = 1.97, 95% CI 1.35-2.89, P = 0.0004, respectively). In conclusion, these data suggest a dissociation of graft-versus-leukemia effects from GVHD in patients with active AML treated with PTCy-based Haplo-HCT.
650    _2
$a lidé $7 D006801
650    _2
$a haploidentická transplantace $x škodlivé účinky $7 D000075442
650    _2
$a nepříbuzný dárce $7 D061349
650    _2
$a cyklofosfamid $x terapeutické užití $7 D003520
650    12
$a nemoc štěpu proti hostiteli $x etiologie $x prevence a kontrola $x farmakoterapie $7 D006086
650    12
$a akutní myeloidní leukemie $x farmakoterapie $7 D015470
650    12
$a transplantace hematopoetických kmenových buněk $x škodlivé účinky $7 D018380
650    _2
$a recidiva $7 D012008
650    _2
$a příprava pacienta k transplantaci $x škodlivé účinky $7 D019172
650    _2
$a retrospektivní studie $7 D012189
655    _2
$a dopisy $7 D016422
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Labopin, Myriam $u EBMT Paris Study Office/CEREST-TC, Paris, France $u Department of Hematology, Saint Antoine Hospital, Paris, France $u INSERM UMR 938, Paris, France $u Sorbonne University, Paris, France
700    1_
$a Tischer, Johanna $u Department of Internal Medicine III, LMU, University Hospital of Munich, Campus Grosshadern, Munich, Germany
700    1_
$a Raiola, Anna Maria $u IRCCS Ospedale Policlinico San Martino, Genoa, Italy
700    1_
$a Vydra, Jan $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Blaise, Didier $u Programme de Transplantation et d'immunothérapie Cellulaire, Management Sport Cancer Lab, Institut Paoli Calmettes, Aix Marseille University, Marseille, France
700    1_
$a Chiusolo, Patrizia $u Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
700    1_
$a Stölzel, Friedrich $u University Hospital Dresden, Medizinische Klinik und Poliklinik, TU Dresden, Dresden, Germany $u University Hospital Schleswig-Holstein, Kiel, Germany
700    1_
$a Fanin, Renato $u Division of Hematology, Azienda Ospedaliero Universitaria di Udine, Udine, Italy
700    1_
$a Chevallier, Patrice $u Dept. D`Hematologie, CHU Nantes, Nantes, France
700    1_
$a Nagler, Arnon $u Division of Hematology and Bone Marrow Transplantation, The Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel
700    1_
$a Ciceri, Fabio $u Haematology and BMT, Ospedale San Raffaele S.R.L., Milan, Italy
700    1_
$a Mohty, Mohamad $u EBMT Paris Study Office/CEREST-TC, Paris, France $u Department of Hematology, Saint Antoine Hospital, Paris, France $u INSERM UMR 938, Paris, France $u Sorbonne University, Paris, France $7 xx0317729
773    0_
$w MED00165458 $t Journal of hematology & oncology $x 1756-8722 $g Roč. 16, č. 1 (2023), s. 10
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36782226 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20240528143556 $b ABA008
999    __
$a ok $b bmc $g 1924698 $s 1190396
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 16 $c 1 $d 10 $e 20230213 $i 1756-8722 $m Journal of hematology & oncology $n J Hematol Oncol $x MED00165458
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace